This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
The cough hypersensitivity syndrome market size has grown strongly in recent years. It will grow from $10.36 billion in 2024 to $11.03 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to increased awareness, telemedicine and remote monitoring, public health initiatives, research funding.
The cough hypersensitivity syndrome market size is expected to see strong growth in the next few years. It will grow to $14.65 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to global health access, patient advocacy and support, quality of life improvements. Major trends in the forecast period include improved diagnosis and screening tools, personalized treatment approaches, new medications.
The growing prevalence of chronic respiratory diseases is anticipated to drive the expansion of the cough hypersensitivity syndrome market. Chronic respiratory diseases (CRDs) encompass a range of long-term conditions affecting the lungs and airways, which lead to ongoing breathing challenges and gradual declines in lung function. Treatment for cough hypersensitivity syndrome helps alleviate symptoms, improve respiratory function, and enhance the quality of life for individuals with CRDs, such as asthma. For example, in June 2023, the Australian Institute of Health and Welfare reported that nearly 30% of the Australian population, or 7.5 million people, are affected by chronic respiratory diseases. Additionally, in May 2024, the National Center for Health Statistics (NCHS) in the United States indicated that adult asthma prevalence increased from 8.4% in 2021 to 8.7% in 2022, with asthma episode incidence for adults rising from 3.3% to 3.7% over the same period. Thus, the increasing occurrence of chronic respiratory diseases is fueling growth in the cough hypersensitivity syndrome market.
The increasing population of cigarette smokers is anticipated to be a significant factor propelling the expansion of the cough hypersensitivity syndrome market in the foreseeable future. Cigarette smokers are individuals who regularly engage in tobacco use by smoking cigarettes, involving the inhalation of smoke generated from burning tobacco leaves encased in a paper-wrapped cylinder. Cigarette smoking induces cough hypersensitivity syndrome by provoking irritation in the airways, inciting inflammation, and causing damage to lung tissues. For instance, as of July 2022, Statistics Canada reported a 5.8% increase in cigarette production compared to June 2021. Additionally, the total number of cigarettes sold rose by 1.3%, reaching 1.4 billion in June 2022. Furthermore, in May 2023, the Centers for Disease Control and Prevention revealed that an estimated 28.3 million U.S. adults are cigarette smokers, with about 3.08 million U.S. middle and high school students using at least one tobacco product. Each day, approximately 1,600 U.S. youth under the age of 18 try their first cigarette. Therefore, the growing population of cigarette smokers is expected to drive the growth of the cough hypersensitivity syndrome market.
Leading companies in the cough hypersensitivity syndrome market are prioritizing the development of advanced asthma treatments, such as rescue inhalers, to enhance patient outcomes and improve quality of life. Asthma rescue inhalers are compact devices designed to deliver quick-relief medication, helping to open airways rapidly. They provide relief from sudden coughing fits by temporarily easing airway sensitivity and reducing cough-related obstructions. For example, in April 2024, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, entered a partnership with Launch Therapeutics, a clinical development firm in the United States. This collaboration focuses on accelerating the clinical program for Teva's ICS-SABA inhaler, TEV-‘248, which combines fluticasone propionate and albuterol sulfate, and is intended for both adult and pediatric asthma patients. This effort also aims to decrease dependency on generic treatments.
In June 2023, GlaxoSmithKline PLC, a prominent UK-based pharmaceutical and biotechnology company specializing in the production of drugs for cough hypersensitivity syndrome, completed the acquisition of Bellus Health Inc. for $2 billion. Through this strategic move, GSK aims to bolster its array of respiratory medications, as well as enhance its capabilities in research and development, production, and commercialization. Bellus Health Inc. is a biotechnology company based in Canada, known for its development of drugs tailored for cough hypersensitivity syndrome.
Major companies operating in the cough hypersensitivity syndrome market are Pfizer Inc., Johnson and Johnson Ltd., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck and Co Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Wyeth Pharmaceuticals Inc., AstraZeneca Pharmaceuticals LP, Teva Pharmaceutical Industries Ltd., Mylan N.V., Lupin Limited, Cadila Pharmaceuticals, Almirall S.A., Akorn Operating Company LLC, Kudco Ireland Ltd., Prestige Consumer Healthcare Inc., GMP Laboratories of America Inc., The Betty Mills Company, Acura Pharmaceuticals Inc.
North America was the largest region in the cough hypersensitivity syndrome market in 2024. The regions covered in cough hypersensitivity syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cough hypersensitivity syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The cough hypersensitivity syndrome market consists of sales of cough suppressants, steam inhalers and humidifiers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Cough hypersensitivity syndrome (CHS) is a medical condition characterized by an exaggerated and abnormal response of the cough reflex to various stimuli, often leading to persistent and chronic coughing. It is commonly associated with conditions such as asthma, gastroesophageal reflux disease (GERD), and upper airway disorders.
The main drug types used for treating cough hypersensitivity syndrome include inhaled corticosteroids, antitussive agents, short-acting beta-2 agonists, anticholinergics, proton pump inhibitors, antihistamines, and others. Inhaled corticosteroids (ICS) refer to a class of medications used in the treatment of various respiratory conditions. These drugs can be administered orally, through inhalation, or by other means. They are utilized by various end-users, including hospitals, specialty clinics, homecare services, and others.
The cough hypersensitivity syndrome market research report is one of a series of new reports that provides cough hypersensitivity syndrome market statistics, including cough hypersensitivity syndrome industry global market size, regional shares, competitors with a cough hypersensitivity syndrome market share, detailed cough hypersensitivity syndrome market segments, market trends and opportunities and any further data you may need to thrive in the cough hypersensitivity syndrome industry. This cough hypersensitivity syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The cough hypersensitivity syndrome market size has grown strongly in recent years. It will grow from $10.36 billion in 2024 to $11.03 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to increased awareness, telemedicine and remote monitoring, public health initiatives, research funding.
The cough hypersensitivity syndrome market size is expected to see strong growth in the next few years. It will grow to $14.65 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to global health access, patient advocacy and support, quality of life improvements. Major trends in the forecast period include improved diagnosis and screening tools, personalized treatment approaches, new medications.
The growing prevalence of chronic respiratory diseases is anticipated to drive the expansion of the cough hypersensitivity syndrome market. Chronic respiratory diseases (CRDs) encompass a range of long-term conditions affecting the lungs and airways, which lead to ongoing breathing challenges and gradual declines in lung function. Treatment for cough hypersensitivity syndrome helps alleviate symptoms, improve respiratory function, and enhance the quality of life for individuals with CRDs, such as asthma. For example, in June 2023, the Australian Institute of Health and Welfare reported that nearly 30% of the Australian population, or 7.5 million people, are affected by chronic respiratory diseases. Additionally, in May 2024, the National Center for Health Statistics (NCHS) in the United States indicated that adult asthma prevalence increased from 8.4% in 2021 to 8.7% in 2022, with asthma episode incidence for adults rising from 3.3% to 3.7% over the same period. Thus, the increasing occurrence of chronic respiratory diseases is fueling growth in the cough hypersensitivity syndrome market.
The increasing population of cigarette smokers is anticipated to be a significant factor propelling the expansion of the cough hypersensitivity syndrome market in the foreseeable future. Cigarette smokers are individuals who regularly engage in tobacco use by smoking cigarettes, involving the inhalation of smoke generated from burning tobacco leaves encased in a paper-wrapped cylinder. Cigarette smoking induces cough hypersensitivity syndrome by provoking irritation in the airways, inciting inflammation, and causing damage to lung tissues. For instance, as of July 2022, Statistics Canada reported a 5.8% increase in cigarette production compared to June 2021. Additionally, the total number of cigarettes sold rose by 1.3%, reaching 1.4 billion in June 2022. Furthermore, in May 2023, the Centers for Disease Control and Prevention revealed that an estimated 28.3 million U.S. adults are cigarette smokers, with about 3.08 million U.S. middle and high school students using at least one tobacco product. Each day, approximately 1,600 U.S. youth under the age of 18 try their first cigarette. Therefore, the growing population of cigarette smokers is expected to drive the growth of the cough hypersensitivity syndrome market.
Leading companies in the cough hypersensitivity syndrome market are prioritizing the development of advanced asthma treatments, such as rescue inhalers, to enhance patient outcomes and improve quality of life. Asthma rescue inhalers are compact devices designed to deliver quick-relief medication, helping to open airways rapidly. They provide relief from sudden coughing fits by temporarily easing airway sensitivity and reducing cough-related obstructions. For example, in April 2024, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, entered a partnership with Launch Therapeutics, a clinical development firm in the United States. This collaboration focuses on accelerating the clinical program for Teva's ICS-SABA inhaler, TEV-‘248, which combines fluticasone propionate and albuterol sulfate, and is intended for both adult and pediatric asthma patients. This effort also aims to decrease dependency on generic treatments.
In June 2023, GlaxoSmithKline PLC, a prominent UK-based pharmaceutical and biotechnology company specializing in the production of drugs for cough hypersensitivity syndrome, completed the acquisition of Bellus Health Inc. for $2 billion. Through this strategic move, GSK aims to bolster its array of respiratory medications, as well as enhance its capabilities in research and development, production, and commercialization. Bellus Health Inc. is a biotechnology company based in Canada, known for its development of drugs tailored for cough hypersensitivity syndrome.
Major companies operating in the cough hypersensitivity syndrome market are Pfizer Inc., Johnson and Johnson Ltd., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck and Co Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Wyeth Pharmaceuticals Inc., AstraZeneca Pharmaceuticals LP, Teva Pharmaceutical Industries Ltd., Mylan N.V., Lupin Limited, Cadila Pharmaceuticals, Almirall S.A., Akorn Operating Company LLC, Kudco Ireland Ltd., Prestige Consumer Healthcare Inc., GMP Laboratories of America Inc., The Betty Mills Company, Acura Pharmaceuticals Inc.
North America was the largest region in the cough hypersensitivity syndrome market in 2024. The regions covered in cough hypersensitivity syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cough hypersensitivity syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The cough hypersensitivity syndrome market consists of sales of cough suppressants, steam inhalers and humidifiers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Cough hypersensitivity syndrome (CHS) is a medical condition characterized by an exaggerated and abnormal response of the cough reflex to various stimuli, often leading to persistent and chronic coughing. It is commonly associated with conditions such as asthma, gastroesophageal reflux disease (GERD), and upper airway disorders.
The main drug types used for treating cough hypersensitivity syndrome include inhaled corticosteroids, antitussive agents, short-acting beta-2 agonists, anticholinergics, proton pump inhibitors, antihistamines, and others. Inhaled corticosteroids (ICS) refer to a class of medications used in the treatment of various respiratory conditions. These drugs can be administered orally, through inhalation, or by other means. They are utilized by various end-users, including hospitals, specialty clinics, homecare services, and others.
The cough hypersensitivity syndrome market research report is one of a series of new reports that provides cough hypersensitivity syndrome market statistics, including cough hypersensitivity syndrome industry global market size, regional shares, competitors with a cough hypersensitivity syndrome market share, detailed cough hypersensitivity syndrome market segments, market trends and opportunities and any further data you may need to thrive in the cough hypersensitivity syndrome industry. This cough hypersensitivity syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Cough Hypersensitivity Syndrome Market Characteristics3. Cough Hypersensitivity Syndrome Market Trends and Strategies4. Cough Hypersensitivity Syndrome Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, Covid and Recovery on the Market32. Global Cough Hypersensitivity Syndrome Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Cough Hypersensitivity Syndrome Market34. Recent Developments in the Cough Hypersensitivity Syndrome Market
5. Global Cough Hypersensitivity Syndrome Growth Analysis and Strategic Analysis Framework
6. Cough Hypersensitivity Syndrome Market Segmentation
7. Cough Hypersensitivity Syndrome Market Regional and Country Analysis
8. Asia-Pacific Cough Hypersensitivity Syndrome Market
9. China Cough Hypersensitivity Syndrome Market
10. India Cough Hypersensitivity Syndrome Market
11. Japan Cough Hypersensitivity Syndrome Market
12. Australia Cough Hypersensitivity Syndrome Market
13. Indonesia Cough Hypersensitivity Syndrome Market
14. South Korea Cough Hypersensitivity Syndrome Market
15. Western Europe Cough Hypersensitivity Syndrome Market
16. UK Cough Hypersensitivity Syndrome Market
17. Germany Cough Hypersensitivity Syndrome Market
18. France Cough Hypersensitivity Syndrome Market
19. Italy Cough Hypersensitivity Syndrome Market
20. Spain Cough Hypersensitivity Syndrome Market
21. Eastern Europe Cough Hypersensitivity Syndrome Market
22. Russia Cough Hypersensitivity Syndrome Market
23. North America Cough Hypersensitivity Syndrome Market
24. USA Cough Hypersensitivity Syndrome Market
25. Canada Cough Hypersensitivity Syndrome Market
26. South America Cough Hypersensitivity Syndrome Market
27. Brazil Cough Hypersensitivity Syndrome Market
28. Middle East Cough Hypersensitivity Syndrome Market
29. Africa Cough Hypersensitivity Syndrome Market
30. Cough Hypersensitivity Syndrome Market Competitive Landscape and Company Profiles
31. Cough Hypersensitivity Syndrome Market Other Major and Innovative Companies
35. Cough Hypersensitivity Syndrome Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Cough Hypersensitivity Syndrome Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on cough hypersensitivity syndrome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cough hypersensitivity syndrome? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cough hypersensitivity syndrome market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Drug Class: Inhales Corticosteroids; Antitussive Agents; Short-acting Beta-2 Agonists; Anticholinergics; Proton Pump Inhibitors; Antihistamines; Other Drugs2) By Route of Administration: Oral; Inhalation; Other Route Of Administration
3) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users
Subsegments:
1) By Inhaled Corticosteroids: Budesonide; Fluticasone; Beclomethasone2) By Antitussive Agents: Dextromethorphan; Codeine; Benzonatate
3) By Short-acting Beta-2 Agonists: Albuterol; Levalbuterol
4) By Anticholinergics: Ipratropium Bromide; Tiotropium
5) By Proton Pump Inhibitors: Omeprazole; Esomeprazole; Lansoprazole
6) By Antihistamines: Cetirizine; Loratadine; Diphenhydramine
7) By Other Drugs: Mucolytics; Combination Therapy Drugs
Key Companies Mentioned: Pfizer Inc.; Johnson and Johnson Ltd.; F. Hoffmann-La Roche AG; Bayer AG; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this Cough Hypersensitivity Syndrome market report include:- Pfizer Inc.
- Johnson and Johnson Ltd.
- F. Hoffmann-La Roche AG
- Bayer AG
- Novartis AG
- Merck and Co Inc.
- Sanofi S.A.
- Bristol-Myers Squibb Company
- AstraZeneca Plc.
- GlaxoSmithKline Plc
- Takeda Pharmaceutical Company Limited
- Boehringer Ingelheim GmbH
- Wyeth Pharmaceuticals Inc.
- AstraZeneca Pharmaceuticals LP
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Lupin Limited
- Cadila Pharmaceuticals
- Almirall S.A.
- Akorn Operating Company LLC
- Kudco Ireland Ltd
- Prestige Consumer Healthcare Inc.
- GMP Laboratories of America Inc.
- The Betty Mills Company
- Acura Pharmaceuticals Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 11.03 Billion |
| Forecasted Market Value ( USD | $ 14.65 Billion |
| Compound Annual Growth Rate | 7.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 26 |
